- CEO
- Jigen Jagdishbhai Modi
- Full Time Employees
- 7
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- 504, Iscon Elegence Circle-P Ahmedabad GU India 380015
- IPO Date
- Mar 30, 2022
- Business
- Achyut Healthcare Limited Achyut Healthcare Limited engages in the manufacturing, trading, and sale of pharmaceutical formulations, active pharmaceutical ingredients (APIs), nutraceuticals, dietary supplements, and medical devices primarily in India with exports to international markets. The company offers products in various forms including tablets, capsules, oral liquids, and injectables; specific offerings encompass generic medications, branded formulations, over-the-counter (OTC) products such as pain relievers and cold remedies, vitamins, minerals, herbal supplements, and specialty pharmaceuticals like immunosuppressants (Cenzure, Arpimune, Azathioprine IP, Everolimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP) alongside items like infrared thermometers and ascorbic acid coated Vitamin C. It provides contract manufacturing services encompassing formulation development, scale-up production, packaging, labeling, and custom API synthesis, while ensuring quality assurance through WHO-GMP compliance and regulatory support for product registration and global distribution. Founded in 1996 and headquartered at 610 Colonade, behind Iscon Temple, opposite Iscon BRTS Bus Stand, Ahmedabad, Gujarat, India, Achyut Healthcare operates in the pharmaceuticals and healthcare sector targeting domestic and export customers including pharmaceutical companies and end-users. Recent developments include promoter Akshit M. Raychahuf increasing his stake from 1.42% to 1.44% via acquisition of 63,000 shares on November 12, 2025; regularization of independent directors Parag Dave and Rajesh Sutaria for five years and appointment of Kamlesh M Shah & Co. as secretarial auditors for 2025-2030 at the 30th AGM on October 1, 2025; and an upcoming board meeting on October 16, 2025, to approve unaudited H1 results ended September 30, 2025.